View Financial HealthThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsVentyx Biosciences 配当と自社株買い配当金 基準チェック /06Ventyx Biosciences配当金を支払った記録がありません。主要情報n/a配当利回り-0.05%バイバック利回り総株主利回り-0.05%将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesVentyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from S&P Pharmaceuticals Select Industry IndexMar 06+ 2 more updatesEli Lilly and Company (NYSE:LLY) completed the acquisition of Ventyx Biosciences, Inc. (NasdaqGS:VTYX) from New Science Ventures, LLC, Affinity Asset Advisors, LLC, The Vanguard Group, Inc., and others.Mar 05Price target decreased by 12% to US$13.29 Feb 12Eli Lilly and Company (NYSE:LLY) entered into an Agreement and Plan of Merger to acquire Ventyx Biosciences, Inc. (NasdaqGS:VTYX) from New Science Ventures, LLC and others for approximately $1 billion.Jan 08Price target increased by 9.4% to US$15.75 Jan 07Ventyx Biosciences Reportedly in $1 Billion Acquisition Talks with Eli LillyJan 07Founder exercised options and sold US$365k worth of stock Dec 21Ventyx Biosciences Announces Appointment to Advisory BoardDec 02+ 1 more updateVentyx Biosciences: Why Caution Should Remain Nov 11Price target increased by 7.2% to US$12.33 Oct 27New major risk - Revenue and earnings growth Oct 23Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk FactorsOct 23Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Deliver On Growth Plans?Sep 23Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from Russell 2000 Value IndexJun 30+ 10 more updatesVentyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's DiseaseJun 18New minor risk - Share price stability May 17Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Deliver On Growth Plans?May 05Ventyx Biosciences, Inc., Annual General Meeting, Jun 04, 2025Apr 25Ventyx Biosciences, Inc. Announces Appointments to Its Scientific Advisory BoardApr 02New minor risk - Market cap size Mar 14New major risk - Revenue and earnings growth Mar 03Ventyx Biosciences, Inc. Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025Feb 18High number of new and inexperienced directors Feb 02Price target increased by 13% to US$12.00 Jan 15Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on Its Nlrp3 Inhibitor PortfolioJan 14Executive Chairperson recently bought US$301k worth of stock Dec 27Founder recently bought US$960k worth of stock Nov 27We Think Ventyx Biosciences (NASDAQ:VTYX) Needs To Drive Business Growth CarefullyNov 14New major risk - Revenue and earnings growth Nov 08Ventyx Biosciences: Ready To Escape "The Crash Cycle" Nov 04Ventyx Biosciences, Inc. Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024Oct 15Ventyx Biosciences, Inc. announced that it expects to receive $26.99994 million in funding from Aventis Inc.Sep 25Ventyx Biosciences, Inc. Announces Executive AppointmentsAug 31Ventyx Biosciences, Inc. Announces CFO ChangesAug 30Price target decreased by 10.0% to US$10.00 Aug 13Price target increased by 9.8% to US$11.75 Aug 12New major risk - Revenue and earnings growth Aug 11Ventyx Biosciences, Inc. Announces Results from the Phase 2 Trial of Vtx958 in Participants with Moderately to Severely Active Crohn’S DiseaseJul 29Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth?Jul 12Ventyx Biosciences: Slim Chances In A Fat Market (Rating Downgrade) Jul 01Ventyx Biosciences, Inc. Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory MarkersJun 08Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating OfficerMay 18New major risk - Revenue and earnings growth May 10Ventyx Biosciences, Inc. to Report Q1, 2024 Results on May 09, 2024May 03Ventyx Biosciences, Inc., Annual General Meeting, Jun 05, 2024Apr 28Price target increased by 13% to US$10.90 Mar 12Ventyx Pivots To Obesity Amid Transformation Mar 12Ventyx Biosciences, Inc. Reports Clinical Data for Its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor EventMar 11Ventyx Biosciences, Inc. announced that it expects to receive $100.0073 million in fundingMar 08Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Ventyx Biosciences, Inc. and Encourages Investors to Contact the FirmMar 05Price target increased by 8.9% to US$9.67 Mar 01New major risk - Revenue and earnings growth Feb 29Here's Why We're Watching Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn SituationFeb 15Ventyx: Too Risky Right Now After Some Poor Data Jan 18Founder recently sold US$125k worth of stock Dec 24Founder notifies of intention to sell stock Dec 22Ventyx Biosciences, Inc. Announces Executive ChangesNov 24New major risk - Revenue and earnings growth Nov 10Price target decreased by 26% to US$40.20 Nov 07Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-To-Severely Active Ulcerative ColitisOct 10Chief Business Officer notifies of intention to sell stock Oct 05Companies Like Ventyx Biosciences (NASDAQ:VTYX) Are In A Position To Invest In GrowthSep 21President & Chief Medical Officer notifies of intention to sell stock Sep 03New minor risk - Share price stability Aug 17Ventyx Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023Aug 04Chief Financial Officer notifies of intention to sell stock Jul 28Chief Scientific Officer notifies of intention to sell stock Jul 06New minor risk - Share price stability Jul 05President & Chief Medical Officer notifies of intention to sell stock Jun 26Ventyx Biosciences, Inc. Announces Initiation of Dosing in A Phase 1 Trial of VTX3232, A Novel CNS-Penetrant NLRP3 InhibitorJun 15Ventyx Biosciences (NASDAQ:VTYX) Is In A Good Position To Deliver On Growth PlansJun 07President & Chief Medical Officer exercised options and sold US$362k worth of stock Jun 04President & Chief Medical Officer exercised options and sold US$118k worth of stock May 18Ventyx Biosciences, Inc. to Report Q1, 2023 Results on May 11, 2023May 05Chief Financial Officer exercised options and sold US$968k worth of stock Apr 29Chief Financial Officer exercised options and sold US$207k worth of stock Apr 20Executive Chair exercised options and sold US$2.8m worth of stock Apr 02Price target increased by 7.8% to US$55.45 Mar 21We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn RateFeb 20Price target increased by 7.6% to US$55.50 Feb 01Independent Director exercised options and sold US$969k worth of stock Jan 26Ventyx Biosciences, Inc. Announces Board AppointmentsJan 13Founder recently sold US$1.7m worth of stock Dec 26President & Chief Medical Officer exercised options and sold US$1.4m worth of stock Dec 18Chief Scientific Officer recently sold US$1.2m worth of stock Dec 16Chief Financial Officer exercised options and sold US$1.3m worth of stock Dec 08Founder recently sold US$8.7m worth of stock Dec 08決済の安定と成長配当データの取得安定した配当: VTYXの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: VTYXの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Ventyx Biosciences 配当利回り対市場VTYX 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (VTYX)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Pharmaceuticals)2.2%アナリスト予想 (VTYX) (最長3年)0%注目すべき配当: VTYXは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: VTYXは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: VTYXの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: VTYXが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/03/05 07:08終値2026/03/03 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Ventyx Biosciences, Inc. 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Hiroshi ShibutaniGoldman SachsMichael YeeJefferies LLCAndrew TsaiJefferies LLC
Ventyx Biosciences, Inc.(NasdaqGS:VTYX) dropped from S&P Pharmaceuticals Select Industry IndexMar 06+ 2 more updates
Eli Lilly and Company (NYSE:LLY) completed the acquisition of Ventyx Biosciences, Inc. (NasdaqGS:VTYX) from New Science Ventures, LLC, Affinity Asset Advisors, LLC, The Vanguard Group, Inc., and others.Mar 05
Eli Lilly and Company (NYSE:LLY) entered into an Agreement and Plan of Merger to acquire Ventyx Biosciences, Inc. (NasdaqGS:VTYX) from New Science Ventures, LLC and others for approximately $1 billion.Jan 08
Ventyx Biosciences Announces Positive Topline Results from Phase 2 Study of VTX3232 in Participants with Obesity and Cardiovascular Risk FactorsOct 23
Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's DiseaseJun 18
Ventyx Biosciences, Inc. Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025Feb 18
Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on Its Nlrp3 Inhibitor PortfolioJan 14
Ventyx Biosciences, Inc. Presents New 52-Week Results from the Phase 2 Trial of VTX002 (Tamuzimod) in Ulcerative Colitis at UEG Week 2024Oct 15
Ventyx Biosciences, Inc. announced that it expects to receive $26.99994 million in funding from Aventis Inc.Sep 25
Ventyx Biosciences, Inc. Announces Results from the Phase 2 Trial of Vtx958 in Participants with Moderately to Severely Active Crohn’S DiseaseJul 29
Ventyx Biosciences, Inc. Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory MarkersJun 08
Ventyx Biosciences, Inc. Reports Clinical Data for Its NLRP3 Inhibitor Portfolio and Provides Pipeline Updates at Virtual Investor EventMar 11
Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Ventyx Biosciences, Inc. and Encourages Investors to Contact the FirmMar 05
Ventyx Biosciences Announces Positive Results from the Phase 2 Trial of VTX002 in Patients with Moderate-To-Severely Active Ulcerative ColitisOct 10
Ventyx Biosciences, Inc. Announces Initiation of Dosing in A Phase 1 Trial of VTX3232, A Novel CNS-Penetrant NLRP3 InhibitorJun 15
